Plain-English translation of NCT05787795 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →This study aims to detect multiple sclerosis (MS) in its earliest stages — before you have any symptoms — by looking for immune system changes in blood, tissue, and fluid samples. Researchers believe that catching MS early and starting treatment could prevent or delay serious disability. You would help them learn which early warning signs matter most.
MS often damages the nervous system silently for years before causing noticeable symptoms. By the time symptoms appear, significant damage may have already occurred. This research seeks to catch the disease much earlier, when treatment is most effective at preventing long-term disability.
You likely qualify if…
You likely don't qualify if…
You would have one required in-person visit lasting about an hour, where researchers will take a blood sample and an oral swab, and you'll answer some health questions. After that, the research team will contact you once a year by phone or email for about 30 minutes to check in. If you agree to additional optional testing — such as spinal fluid collection, tissue biopsies, or brain MRI scans — you would have extra visits that might last up to 3 hours each.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States
Sponsor
Yale University
Collaborators
Roche-Genentech
Enrollment target
~1,000 participants
Started
June 2022
Primary completion
June 2032
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Erin Longbrake, MD
Yale University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.